The information on this site is intended for healthcare professionals involved in the delivery of critical care, surgery, and diagnostics. By entering, you confirm you are a qualified healthcare professional or an authorised representative.
TheronTech builds the machines that buy clinicians time. Across three divisions, every device is a bridge: it supports a failing system, replaces a function the body has lost, or surfaces the data that changes the next decision. Meet the people who put them in the room.
TheronTech is proudly owned and operated by Vilardo Holdings (Global Holdings · Asset Management & Strategic Solutions). Vilardo is a perfectly legitimate, fully diversified investment group with absolutely nothing to hide, and TheronTech is the crown jewel of its clean, above-board, entirely-by-the-book medical portfolio. Any rumours to the contrary are slanderous and, frankly, hurtful.
Each division is led by a clinical sales specialist who actually knows the floor. They support live cases, run education that isn't a sales pitch, and stay registered so the knowledge stays current.

Breathes for a patient who can't. Adaptive pressure support, lung-protective modes built on ARDSNet principles.1

Takes over the heart, the lungs, or both. VV and VA support for failure that won't respond to anything else.2,3

Does the kidney's job continuously over hours or days. CVVH, CVVHD, CVVHDF, KDIGO-aligned dosing.4,5

Measures pressures, flows, and oxygen delivery in real time. Continuous cardiac output and fluid responsiveness.

Delivers drugs in fractions of a millilitre. Syringe drivers, volumetric pumps, dose-error reduction built in.

Heated, humidified oxygen up to 80 L/min before a ventilator is needed.6

Holds the thermal environment a premature infant can't yet regulate. Servo-controlled warming and humidity.











A thin camera on a tube. Goes into the bladder or up to the kidney to look, diagnose, or treat. No incision.

Kidney stones broken up by laser or shock waves until they turn to dust and pass. No cutting.

A small implant that signals the nerves controlling bladder and bowel. For overactive bladder when other options haven't worked.

An implanted cuff replacing the muscle that controls urine flow. Used after prostate surgery. Manually operated.

Measures how the bladder stores and releases. Diagnostic, not treatment, tells the surgeon what's actually wrong.

Tubes that keep things open or drain fluid. Unglamorous, essential.
The prostate enlarges with age and squeezes the urethra. Weak flow, urgency, up five times a night. Common, rarely discussed.
Radioactive seeds placed directly into the prostate. The guidance system gets the placement exactly right.
Stress incontinence, prolapse, overactive bladder, recurrent UTIs. Underdiagnosed, underdiscussed, very much his portfolio.













The big scanners. The ones that cost more than the building's car park and take six weeks to install.
Live X-ray imaging in theatre so the surgeon can see what they're doing in real time.
Where every scan lives, gets stored, and gets pulled up. The plumbing radiology runs on.
Software that flags, measures, and prioritises. Useful when it works, embarrassing when it's oversold.
Turns a radiologist's findings into clean, consistent, searchable reports instead of free-text chaos.
Contrast, coils, detectors, the parts that wear out. Boring, dependable, pays the bills.






Critical Care. The foundation for modern ICU ventilation comes from the landmark ARDSNet trial, which showed lung-protective ventilation with lower tidal volumes cut ARDS mortality by roughly 9% absolute.1 ECMO for severe respiratory failure is supported by the CESAR2 and EOLIA3 trials. CRRT dosing was settled by the VA/NIH ATN study4 and the RENAL study,5 both finding no mortality benefit above 20–25 mL/kg/h. High-flow nasal cannula entered the evidence base with FLORALI, which showed reduced intubation and improved survival in acute hypoxaemic respiratory failure.6
Urology. Stone management, scope selection, and laser-versus-shockwave decisions follow the EAU Guidelines on Urolithiasis7 and the AUA/Endourological Society guideline on surgical management of stones,8 which set out when ureteroscopy, shockwave lithotripsy, or a percutaneous approach is the right call.
Medical Imaging. Modality choice, contrast use, and appropriate ordering are governed by the ACR Appropriateness Criteria, the most comprehensive evidence-based guidelines for diagnostic imaging and image-guided intervention.9
References 1–6 support the Critical Care division, 7–8 the Urology division, and 9 the Medical Imaging division. All are real, published clinical guidelines and trials, cited for educational context within a fictional project.
IMPORTANT NOTICE: TheronTech is a fictional company created for illustrative and creative purposes only. No products described on this page exist. No medical devices are being marketed, sold, or distributed. This page does not constitute medical advice, product promotion, or regulatory submission.
OWNERSHIP: TheronTech is a fictional subsidiary of the equally fictional Vilardo Holdings. The "clean acquisition" framing is a tongue-in-cheek bit of worldbuilding. Vilardo Holdings is portrayed as entirely above-board, and there is nothing untoward about them whatsoever.
REGULATORY DISCLAIMER: All product names (AeraStar, CardioLink, AquaClear, PulseMap, InfuDose, FlowTherapy, NeoGuard) are fictional designations. Any resemblance to actual marketed devices is coincidental.
CLINICAL REFERENCES: The peer-reviewed references above are real, published studies included for educational context only. Clinicians should consult full texts and current institutional guidelines before making treatment decisions.
CONTACT INFORMATION: All representatives listed are fictional characters. Any contact links lead to creative-writing roleplay, not real sales contacts.
© 2025 TheronTech, Inc. [FICTIONAL] · A Vilardo Holdings Company [ALSO FICTIONAL] · All rights reserved.